We bring you the latest news from the healthcare about the health care in the United Kingdom.

zaterdag 10 maart 2018

The Lancet: [News] Larotrectinib in TRK fusion-positive cancers

[News] Larotrectinib in TRK fusion-positive cancers
The TRK inhibitor larotrectinib is associated with a high proportion of patients achieving an overall response with TRK fusion-positive cancers, according to a new combined analysis of three trials.
Read more

[News] Dasatinib in paediatric chronic myeloid leukaemias
Treatment with the tyrosine kinase inhibitor (TKI) dasatinib achieved clinically important responses in paediatric patients with chronic myeloid leukaemia (CML) in a phase 2, non-randomised trial.
Read more

[News] Colorectal adenoma risk in childhood cancer survivors
Survivors of childhood cancer treated with abdominopelvic radiotherapy, total body irradiation, or cisplatin have an increased risk of developing colorectal adenomas and carcinomas, according to a retrospective cohort study.
Read more

[Comment] Aiming for complete responses in renal-cell carcinoma
Treatments for metastatic renal-cell carcinoma have evolved rapidly in the past decade, and since 2006, targeted therapies have been the cornerstone of treatments, with pazopanib or sunitinib leading to objective responses in 24–31% of patients.1 Deep tumour responses have been described as a surrogate measure for overall survival in patients with renal-cell carcinoma.2 However, because these are rarely achieved with current standard first-line targeted therapies, novel tyrosine-kinase inhibitors (TKIs) are being tested.
Read more

[Articles] Vulvar field resection based on ontogenetic cancer field theory for surgical treatment of vulvar carcinoma: a single-centre, single-group, prospective trial
Our results support the theory of ontogenetic cancer fields for vulvar carcinoma, accord with our previous findings in cervical cancer, and suggest the general applicability of the theory. Application of the concept of cancer field resection could improve outcomes in patients with vulvar carcinoma, but needs to be investigated further in multicentre randomised controlled trials.
Read more